Loading...

AQST AQUESTIVE THERAPEUTICS INC Product Launches 8-K Filing

QSTV

QST

AQUESTIVE THERAPEUTICS INC

(AQST)

2024 8-K

Show Summary

Show Summary

Financial Statements

Pediatric Study Results

Investor Presentation

Financial Results

Presentation Announcement

Financial Update

FDA Approval News

Board Resignation

Investor Presentation

Q3 Earnings Report

Product Presentation

Positive Study Results

Bylaw Amendments

Investor Day Announcement

Investor Presentations

Financial Results Announcement

Positive PK data for Anaphy...

Annual Meeting Voting Results

Disclosure of Information

Promotion of Cassie Jung to...

Disclosure of Investor Pres...

Financial Results Announcement

FDA Approval and Clinical D...

Appointment of Director

Public Offering

Clinical Data and FDA Meeting

Financial Results Announcement

Sales Plan Adoption

Phase 3 Clinical Study Init...

Disclosure of Investor Pres...

Financial Results and Busin...

Purchase Agreements and Red...

Business Update

Disclosure of Investor Pres...

Financial Results Announcement

Securities Purchase Agreements

Product Trial Results

Investor Conferences

Annual Meeting Voting Results

Financial Results Announcement

Compliance regained with Na...

Regulation FD Disclosure

Disclosure of Investor Pres...

Financial Results Announcement

Amendment to Commercial Exp...

Bylaws Amendment

External Links:

Aquestive Therapeutics announced positive results from its oral allergy syndrome study for Anaphylm, a potential first non-invasive epinephrine treatment for severe allergic reactions, pending FDA approval.

AI Assistant

AQUESTIVE THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.